Author

J. F. DiPersio

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5 Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Approach:experimental assay· 4 Approach:statistical model· 4 Assay:bulk RNA-seq· 3 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2

Frequent Co-Authors

M. P. Rettig· 5 shared B. Lowenberg· 2 shared C. Miller· 2 shared D. C. Link· 2 shared D. H. Spencer· 2 shared E. Chendamarai· 2 shared H. Altmann· 2 shared J. E. Payton· 2 shared

Activity by Year

2019-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

M. P. Rettig

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Rational protein engineering to enhance MHC-independent T cell receptors

J. Chang, J. H. Landmann, T.-C. Chang, Y. Tenzin, J. M. Warrington, M. E. Selli, J. Ritchey, Y.-S. Hsu, M. Slade, D. K. Gupta, J. F. DiPersio, N. Singh

The paper designs MHC-independent T cell receptors (miTCRs) to enhance cancer immunotherapy by improving receptor stability and function through structural modeling and iterative sequence modifications.

bioRxiv · Feb 22, 2024Immunology

Streptavidin-drug conjugates streamline optimization of antibody-based conditioning for hematopoietic stem cell transplantation

A. R. Yelamali, E. Chendamarai, J. K. Ritchey, M. P. Rettig, J. F. DiPersio, S. P. Persaud

This paper develops a streptavidin-drug conjugate platform to efficiently optimize antibody-based conditioning for HSCT, finding that PBD dimer SGD-1882 is most effective for targeting HSCs and AML cells.

bioRxiv · Feb 12, 2024Immunology

Immunosuppression and Outcomes in Acute Myeloid Leukemia

F. Ferraro, C. Miller, K. Christensen, N. M. Helton, M. O'Laughlin, C. C. Fronick, R. S. Fulton, J. Kohlschmidt, A.-K. Eisfeld, C. D. Bloomfield, S. M. Ramakrishnan, R. B. Day, L. D. Wartman, G. L. Uy, J. S. Welch, , T. J. Ley

This study identifies immunosuppressive features in AML cells associated with poor outcomes in patients treated with standard chemotherapy.

bioRxiv · Sep 3, 2021 · PreprintCancer Biology

Genome-wide analysis of focal DNA hypermethylation in IDH-mutant AML samples

E. R. Wilson, N. Helton, S. E. Heath, R. S. Fulton, C. Miller, J. E. Payton, J. S. Welch, M. Walter, P. Westervelt, J. F. DiPersio, D. C. Link, T. J. Ley, D. H. Spencer

This study identifies focal DNA hypermethylation in IDH-mutant AML samples and links it to TET2 and DNMT3A activity, with implications for AML pathogenesis.

bioRxiv · Mar 3, 2021 · PreprintCancer Biology

Apolipoprotein M attenuates anthracycline cardiotoxicity and lysosomal injury

Z. Guo, C. Valenzuela Ripoll, A. Picataggi, D. R. Rawnsley, M. Ozcan, J. A. Chirinos, E. Chendamarai, A. Girardi, T. Riehl, H. Evie, A. Diab, A. Kovacs, K. Hyrc, X. Ma, A. Asnani, , A. Javaheri

This paper investigates the role of apolipoprotein M in anthracycline cardiotoxicity, finding that ApoM protects against cardiac dysfunction and lysosomal injury through the autophagy-lysosome pathway.

bioRxiv · Jan 12, 2021Pharmacology & Toxicology

Antibody-drug conjugates targeting CD45 plus Janus kinase inhibitors effectively condition for allogeneic hematopoietic stem cell transplantation

S. P. Persaud, J. K. Ritchey, J. Choi, P. G. Ruminski, M. L. Cooper, M. P. Rettig, J. F. DiPersio

This study shows that combining CD45-targeted ADCs with baricitinib enables effective allogeneic HSCT with high donor chimerism and reduced graft-versus-host disease.

bioRxiv · Oct 2, 2020Immunology

TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia

C. Lai, J. Vadakekolathu, S. Reeder, S. E. Church, T. Hood, I. Aldoss, J. Godwin, M. J. Wieduwilt, M. Arellano, J. Muth, F. Ravandi, K. Sweet, H. Altmann, G. A. Foulds, F. Stolzel, , S. Rutella

This paper shows TP53 mutations in AML are linked to immune features and improved response to flotetuzumab immunotherapy.

bioRxiv · Feb 28, 2020 · PreprintImmunology

Immune Landscapes Predict Chemotherapy Resistance And Immunotherapy Response In Acute Myeloid Leukemia

J. Vadakekolathu, M. D. Minden, T. Hood, S. E. Church, S. Reeder, H. Altmann, A. H. Sullivan, E. J. Viboch, T. Patel, N. Ibrahimova, S. E. Warren, A. Arruda, Y. Liang, J. Muth, M. Schmitz, , S. Rutella

This study identifies immune subtypes in AML and shows that IFN-gamma profiles predict chemotherapy resistance and immunotherapy response.

bioRxiv · Jul 26, 2019Immunology